ArticleInternational journal of clinical oncology2025
Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapy.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The use of antibiotic, probiotic, and fecal microbiota transplantation in modulating immunotherapy efficacy and survival: a systematic review and meta-analysis of clinical outcomes.The oncologist · 2026Pooled it
- Antibiotics and probiotics differentially shape immunotherapy outcomes in non-small cell lung cancer.Cancer biology & medicine · 2026Article
- Harnessing the gut microbiota to enhance immune checkpoint inhibitor efficacy: from mechanistic insights to clinical translation.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence suggests that antibiotic (ATB) use may negatively impact the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC). We previously demonstrated that ATB use was significantly associated with decreased survival in NSCLC patients receiving ICI monotherapy. This study aimed to investigate the effect of ATB use on survival in NSCLC patients undergoing combined ICI and chemotherapy. PATIENTS AND
methodsWe evaluated the impact of ATB on survival in NSCLC patients treated with ICIs and chemotherapy in this multicenter retrospective study. We analyzed outcomes such as progression-free survival (PFS) and overall survival (OS) in patients who received ATB within 2 months before or 1 month after starting ICI and chemotherapy combination therapy.
resultsAmong 451 patients, 113 received ATB (ATB group) and 338 did not (ATB-unexposed). The median PFS was 7.1 months in the ATB group and 8.4 months in the ATB-unexposed group. The median OS was 18.0 months in the ATB group compared to 23.8 months in the ATB-unexposed group, indicating a significant reduction in both PFS and OS for the ATB group. Notably, this negative impact was not observed in patients who used probiotics (PFS: 6.0 vs. 7.6 months, p = 0.355; OS: 16.7 months vs. not reached (NR), p = 0.179).
conclusionATB use was significantly associated with poorer survival outcomes in NSCLC patients treated with combined ICI and chemotherapy, but this effect was attenuated by probiotics.
Indexed as
Identifiers
40875069What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.